Hypoglycemic effect of NeuroEPO in diabetic and non-diabetic rats
Keywords:
diabetes mellitus, erythropoietin and cytoprotection, glucose tolerance test, insulin tolerance test, NeuroEPO, streptozotocin.Abstract
Introduction: NeuroEPO is a non-hematopoietic variant of human recombinant erythropoietin, which may have a hypoglycemic effect.
Objectives: To evaluate the influence of NeuroEPO on glycemia in diabetic and non-diabetic rats.
Material and Methods: The experiments were conducted in Wistar rats with streptozotocin-induced diabetes with and without insulin treatment, and in non-diabetic rats with glucose overload. In each experiment, one group received a subcutaneous injection of NeuroEPO (0.5 mg/kg) and the other group received a vehicle. Glycemia was determined in 120 min. Comparisons were made using one-and two-way analysis of variance, followed by the Bonferroni test. The differences were considered significant with p values < 0,05.
Results: In diabetic rats without insulin treatment, glycemic levels decreased significantly in the group that received NeuroEPO. In nondiabetic rats that received NeuroEPO and a glucose overload, glycemia was similar to that in the control group. In diabetic rats that received NeuroEPO and insulin, the glycemia reduction was greater than in the group that only received insulin.
Conclusions: NeuroEPO has a hypoglycemic effect in diabetic rats due to an insulinotropic mechanism that shows synergism with insulin in the treatment of hyperglycemia. However, NeuroEPO does not influence the glucose tolerance in non-diabetic rats, at least immediately. It is necessary to delve into the mechanisms by which NeuroEPO can reduce hyperglycemia and the influence of this substance under conditions of normoglycemia.
Downloads
References
1- Licea ME, Acosta A, Álvarez VA, Aldana D, Arnold Y, Álvarez Y, et al. Diabetes mellitus. Una mirada integral. La Habana: Editorial Ciencias Médicas; 2021. 848 p. ISBN 978-959-313-883-3. Disponible en: http://www.bvscuba.sld.cu/libro/diabetes-mellitus-una-mirada-integral//
2- Bess S, Alonso I, Sánchez E, López LM, editores. Anuario estadístico de salud 2019. La Habana: Ministerio de Salud Pública. Dirección de registros médicos y estadísticas de salud; 2020. 193 p. ISSN 1561-4433. Disponible en:
http://files.sld.cu/bvscuba/files/2020/05/Anuario-Electrónico-Español-2019-ed-2020.pdf
3- American Diabetes Association. Introduction: Standards of medical care in diabetes-2021. Diabetes Care. 2020 Jan; 44(Suppl. 1):S1–S2. doi.10.2337/dc21-Sint
4- Suresh S, Rajvanshi PK and Noguchi CT. The many facets of erythropoietin physiologic and metabolic response. Front Physiol. 2020 Jan; 10:1534. doi: 10.3389/fphys.2019.01534
5- Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020 Feb; 11(2):2-12. doi: 10.1038/s41419-020-2276-8
6- Gholamzadeh R, Eskandari M, Bigdeli MR, Mostafavi H. Erythropoietin pretreatment effect on blood glucose and its relationship with inflammatory factors after brain ischemic-reperfusion injury in rats. Basic Clin Neurosci. 2018 Sep-Oct; 9 (5):347-56. doi: 10.32598/bcn.9.5.347
7- Castillo C, Burgos CF, Hidalgo A, Silva-Grecchi T, Gavilan J, Roberto J, et al. Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor. Neural Regen Res. 2017 Sep; 12 (9):1381-9. doi: 10.4103/1673-5374.215240
8- Rey F, Balsari A, Giallongo T, Ottolenghi S, Di Giulio AM, Samaja M, et al. Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases. ASN Neuro. 2019 Jan-Dec; 11:1-8. doi: 10.1177/1759091419871420
9- Kudenchuck PJ. Erythropoietin for out-of-hospital cardiac arrest: growing together or apart? JACC. 2016 Jul 5; 68(1):50-2. doi: 10.1016/j.jacc.2016.03.598.
10- Bing Liu, Yuzeng Xue, Huali Wei, Junmeng Liu, Na Jia, Ming Lan. Effect of erythropoietin activating EPO-EPOR signaling pathway on improving cardiac function in diabetic rats. Acta Medica Mediterranea. 2020, 36:2999-3004. doi: 10.19193/0393-6384_2020_5_461
11- Zhu M, Wang L, Yang J, Xie K, Zhu M, Liu S, et al. Erythropoietin ameliorates lung injury by accelerating pulmonary endothelium cell proliferation via janus kinase-signal transducer and activator of transcription 3 pathway after kidney ischemia and reperfusion injury. Transplant Proc. 2019 Apr; 51 (3):972-8. doi: 10.1016/j.transproceed.2019.01.059
12- Wu SH, Lu IC, Tai MH, Chai CY, Kwan AL, Huang SH. Erythropoietin alleviates burn-induced muscle wasting. Int J Med Sci. 2020 Jan; 17(1):33-44. doi: 10.7150/ijms.38590
13- Chen L, Sun Q, Liu S, Hu H, Lv J, Ji W, et al. Erythropoietin improves glucose metabolism and pancreatic β-cell damage in experimental diabetic rats. Mol Med Rep. 2015 Oct; 12(4):5391-8. doi: 10.3892/mmr.2015.4006
14- Maiese K. Erythropoietin and diabetes mellitus. World J Diabetes. 2015 Oct 25; 6 (14):1259-73. doi: 10.4239/wjd. v6. i14.1259
15- El-Desouki NI, Tabl GA, Abdel-Aziz KK, Salim EI, Nazeeh N. Improvement in beta-islets of Langerhans in alloxan-induced diabetic rats by erythropoietin and spirulina. JOBAZ. 2015; 71:20-31. doi: 10.1016/j.jobaz.2015.04.003
16- Niu HS, Shan Ch, Niu Sh, Cheng J, Lee K. Erythropoietin ameliorates hyperglycemia in type 1-like diabetic rats. Drug Des Dev Ther. 2016 Jun 3; 10:1877-84. doi: 10.2147/DDDT.S1058677
17- Kuo Sh, Li Y, Cheng KcH, Niu Ch, Cheng J, Niu H. Investigation of the pronounced erythropoietin-induced reduction in hyperglycemia in type 1-like diabetic rats. Endocr J. 2018 Feb 26; 65 (2):181-91. doi: 10.1507/endocrj.EJ17-0353
18- EL Okela AZ, El-Arbagyb AR, Yasseinb YS, Khodirc, Kasemb HE. Effect of erythropoietin treatment on hemoglobin A1c levels in diabetic patients with chronic kidney disease. J Egypt Soc Nephrol Transplant. 2019; 19 (3):86-94. doi: 10.4103/jesnt.jesnt_2_19
19- Rama R, Garzón F, Rodríguez-Cruz Y, Maurice T, García-Rodríguez JC. Neuroprotective effect of Neuro-EPO in neurodegenerative diseases: “Alea jacta est”. Neural Regen Res. 2019 Sep; 14(9):1519-21. doi:10.4103/1673-5374.255968
20- Garzón F, Rodríguez Y, García JC, Rama R. Neuroprotective effects of NeuroEPO using an in vitro model of stroke. Behav Sci (Basel). 2018 Feb 13; 8 (26):1-11. doi:10.3390/bs8020026
21- Garzón F, Coimbra D, Parcerisas A, Rodriguez Y, García JC, Soriano E, et al. NeuroEPO preserves neurons from glutamate-induced excitotoxicity. J Alzheimers Dis. 2018; 65 (4):1469-83 doi: 10.3233/JAD-180668
22- Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G, de la C
García-Barceló M, et al. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅-₃₅ non-transgenic
mouse model of Alzheimer’s disease. J Psychopharmacol. 2013 Nov; 27(11):1044-57. doi: 10.1177/0269881113494939
23- Rodríguez Y, Strehaiano M, Rodríguez T, García JC, Maurice T. An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer’s disease. J Alzheimer´s Dis. 2017; 55(1):231-48. doi: 10.3233/JAD-160500.
24- Santos MO, Díaz MA, Jiménez RD, Pomares IY, Festary CT, González CA, et al. Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study. BMC Neurol. 2017 Jul 4; 7 (1):129. doi: 10.1186/s12883-017-0908-0
25- National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011. 246 p. doi: 10.17226/12910
26- Quinna NA, Badwan AA. impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats. Drug Design, Development and Therapy. 2015 May 5; 9 2515–25. doi: 10.2147/DDDT.S79885.
27- Bowe JE, Franklin ZJ, Hauge-Evans AC, King AJ, Persaud SJ, Jones PM. Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. J Endocrinol. 2014; 222 (3): G13–G25. doi: 10.1530/JOE-14-0182
28. Fernández T, Clapes S, Pérez CL, Barreto J, Fernandez G. Hypoglycemic effect of NeuroEPO in diabetic and non-diabetic rats [Internet]. Mendeley Data, V2, doi: 10.17632/pty6hwbgnw.2 2021 [Citado 19/06/2021]. Disponible en: https://data.mendeley.com/datasets/pty6hwbgnw/2
29- Pan Y, Hong X, Li L, Hong Y, Yan Q, Min H, et al. Erythropoietin reduces insulin resistance via regulation of its receptor-mediated signaling pathways in db/db mice skeletal muscle. Int J Biol Sci. 2017 Oct 17; 13 (10):1329-40. doi: 10.7150/ijbs.19752
30- Klip A, McGraw TE, James DE. Thirty sweet years of GLUT4. J Biol Chem. 2019 Jul 26; 294 (30):11369-8. doi: 10.1074/jbc.REV119.008351
31- Kasemb HE, El-Mohsen WA, Shebla IS, El-Rahman AA, Kamelb MA. Insulin resistance in patients with end-stage renal disease on hemodialysis: effect of short-term erythropoietin therapy. J Egypt Soc Nephrol Transplant. 2020; 20 (2):111-9. doi: 10.4103/jesnt.jesnt_25_19
Download PDF
